Navigation Links
Heparin Based Nanoscale Materials Developed For Dialysis Treatment

In what can be called as a breakthrough in the field of nanotechnology, researchers have been successful in engineering nanoscale biomaterials, using heparin//, an anticoagulant. These blood compatible could revolutionize medical treatments, including dialysis, a routine form of treatment for renal failure patients.

Furthermore, these medical devices could have numerous diagnostic and therapeutic applications that are not foreseen at the moment.

The researchers prepared several materials with heparin composites or coatings, including carbon nanotubes, nanofibers, and membranes with nanosized pores, and then demonstrated the materials' high compatibility with blood. Heparin is a common therapeutic used to maintain blood flow or prevent clotting during medical procedures and treatments.

The researchers demonstrated the composite heparin membrane with nanopores could work as an artificial kidney, or dialyzer, by filtering the blood and maintaining its flow. The presence of this blood-compatible dialyzer could potentially eliminate the need for systemic administration of heparin to the patient during kidney dialysis, the researchers say.

The heparin-coated membranes are described in a paper titled ‘Ionic Liquid-Derived Blood Compatible Membranes for Kidney Dialysis,’ published online Apr. 24 in advance of print in the Journal of Biomedical Materials Research.

‘These heparin composite membranes and fibers and coated carbon nanotubes are an enabling technology,’ says Saravanababu Murugesan, a recent doctoral graduate in chemical and biological engineering at Rensselaer and lead author of the paper. ‘Our results show these novel materials have great promise in the development of improved medical devices that are blood compatible.’

The research team is led by Robert Linhardt, the Ann and John H. Broadbent Jr. '59 Senior Constellation Professor of Bio catalysis and Metabolic Engineering at Rensselaer, and includes collaboration with Pulickel Ajayan, the Henry Burlage Professor of Materials Science and Engineering, and Omkaram ‘Om’ Nalamasu, professor of materials science and engineering, at Rensselaer. Additional co-authors of the paper are Shaker Mousa, director of the Pharmaceutical Research Institute at Albany College of Pharmacy, and Aravind Vijayaraghavan, a recent doctoral graduate in materials science and engineering at Rensselaer. Funding for this research was provided by the National Institutes of Health.

Recent results related to this work have been published online in the journals Langmuir (‘Blood Compatible Nanotubes ??? Nano-based Neoproteoglycans,’ Mar. 11, 2006) and Biomacromolecules (‘Preparation of Biopolymer Fibers by Electrospinning from Room Temperature Ionic Liquids,’ Jan. 26, 2006). Provisional patents have been filed by Rensselaer Polytechnic Institute.

Research in Linhardt's group at the Center for Biotechnology and Interdisciplinary Studies at Rensselaer focuses on complex carbohydrates such as heparin. After determining the structure of these molecules, researchers study their biological activities to establish a structure-activity relationship that may reveal lead compounds for new drug development. Recent discoveries include a synthetic method for preparation of heparin in quantities large enough for use in medical treatment.

Source: Euekalert
'"/>




Related medicine news :

1. Complications In Kidney Failure Patients Linked To Heparin
2. Heparin does not protect from recurrent heart attacks
3. Heparin Antibodies May Put Patients At Risk
4. Ordinary Heparin as Effective as Expensive Blood Thinner
5. Steps To Improve Quality Of Plant-Based Drugs
6. Cancer hazard Found With Animal-Based Nutrients
7. Prime Minister Manmohan Against Incentive-Based Population Control
8. New Oat And Soy-Based Fat Replacer Launched
9. Record Growth Of Soya-Based Dairy Alternatives Over The Past Year In European Markets
10. Race Based Genome Project Launched By Mexico
11. Childhood Asthma Can Be Kept Under Control By Cost-Effective Home Based Interventions
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “The Journey: ... faced every danger possible to save lost souls in the Philippines. “The Journey: From ... Carole is a dedicated teacher of the Bible. She has taught all ages and ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance ... management, will showcase a range of technology and learning solutions at the 68th ... and Expo to be held October 14–18, 2017 at the Mandalay Bay Resort ...
(Date:10/12/2017)... ... 2017 , ... Planet Fitness, one of the largest and fastest growing franchisors ... a flagship location in Covington, LA at 401 N. U.S. Highway 190, in January ... Office Depot in the Holiday Square shopping center. Its location allows it to serve ...
(Date:10/12/2017)... PALM CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... of cold therapy products, announced today the introduction of an innovative new design of ... the multipurpose pad so you get maximum comfort while controlling your pain while using ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, ... post-acute health care, have expanded their existing home health joint venture through an ... has been operating a joint venture home health company with Asante, delivering clinically ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Halo Labs announces the European launch of their new low volume, ... 2017 in Cambridge, U.K on October 4th. ... samples with unprecedented speed and sensitivity while using far less sample ... ... system ...
(Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion ... notable awards. Ranked as number one in the South Florida ... time in Inc. 5000 yearly list, the national specialty pharmacy ... Armando Bardisa will soon be honored by SFBJ ... Set to receive his award in ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
Breaking Medicine Technology: